HCPCS Code J9202: Goserelin acetate implant billing guide

Key Takeaways

HCPCS Code J9202 describes goserelin acetate implant, per 3.6 mg (brand name Zoladex), a GnRH agonist used to treat prostate cancer, breast cancer, endometriosis, and uterine fibroids.

1 billable unit of J9202 equals exactly 3.6 mg. The 10.8 mg three-month depot uses a separate HCPCS code and must never be billed under J9202.

J9202 is subject to CMS JW and JZ modifier requirements for drug wastage reporting. Failing to append the correct modifier is a common cause of claim denial.

Pabau’s claims management software helps oncology and urology practices track drug units, wastage, and payer-specific authorization requirements in one place.

Billing errors on hormonal therapy drugs cost oncology and urology practices thousands of dollars per year in denied claims. For goserelin acetate, the mistake usually happens before the claim is even submitted: the wrong dose, the wrong modifier, or the wrong ICD-10 code attached to an otherwise correct claims management workflow.

HCPCS Code J9202 covers the 3.6 mg monthly implant only. This guide covers code properties, covered ICD-10 diagnoses, NDC codes, Medicare reimbursement methodology, JW/JZ modifier requirements, and payer coverage considerations for oncology and urology billing teams.

HCPCS Code J9202: code description and properties

HCPCS Code J9202 is the Level II code maintained by the Centers for Medicare and Medicaid Services (CMS) for goserelin acetate implant, per 3.6 mg. It falls under the Chemotherapy Drugs category (J9000-J9999) within the HCPCS Level II J-code range.

Goserelin acetate is a synthetic analog of luteinizing hormone-releasing hormone (LHRH). It works by suppressing testosterone in men and estrogen in women through sustained GnRH receptor downregulation. According to the NCI SEER CanMED oncology database, J9202 is classified under Hormonal Therapy as a GnRH Agonist, and was not discontinued as of the most recent database entry.

The code is listed in the CMS JW Modifier and JZ Modifier Policy HCPCS Codes document, confirming that drug wastage reporting rules apply. Providers in men’s health clinics billing for prostate cancer hormonal suppression are among the most frequent users of this code.

3.6 mg vs. 10.8 mg: a critical coding distinction

J9202 covers the 3.6 mg monthly implant only. The 10.8 mg three-month depot formulation (NDC prefix 70720-0951-XX) carries a separate HCPCS code. Billing the 10.8 mg depot under J9202 constitutes an undercoding error and will typically trigger a claim edit. Always verify which formulation was administered before assigning the code.

ICD-10 diagnosis codes covered with HCPCS Code J9202

CMS Article A52453 (Billing and Coding: Luteinizing Hormone-Releasing Hormone Analogs) provides the primary ICD-10 coverage framework for J9202. The article establishes Group 4 primary diagnosis codes and a set of secondary codes that can accompany them. Payers that follow CMS LCD/NCD policy will generally mirror this list, though commercial payers may apply narrower coverage criteria.

Practices treating patients across multiple hormonal conditions, including OB/GYN clinics managing endometriosis and uterine fibroids, should verify which ICD-10 codes their specific payer accepts before billing.

Always submit the most specific ICD-10 code available. For prostate cancer, use C61 as the primary code. For breast cancer, select the site-specific code matching the patient’s diagnosis. Secondary codes may be submitted alongside primary codes per CMS Article A52453 instructions.

Off-label use of goserelin is not covered under Medicare without an applicable ICD-10 code listed in the current CMS coverage article. Document the clinical indication clearly in the patient record before billing. Practices with robust HIPAA-compliant clinic software can attach documentation directly to each claim for audit readiness.

NDC codes and HCPCS J9202 crosswalk

National Drug Codes (NDCs) identify the specific manufactured product administered. When billing J9202 under Medicare and many commercial plans, you must include both the HCPCS code and the corresponding 11-digit NDC on the claim. Using the HCPCS code alone without an NDC will trigger a claim edit on many payer systems.

NDC codes are subject to change as manufacturers update packaging. Verify active NDCs against your pharmacy’s current dispensing label before submitting claims. UHC’s published NDC packaged-drugs list confirms multiple active codes for J9202, including the 70720-0950-XX and 50090-XXXX series.

When billing, report the NDC in the 11-digit format on the CMS-1500 or electronic 837P claim. The unit of measure is typically “UN” (unit) with a quantity of 1 per 3.6 mg implant administered. Good inventory management software can track lot numbers and NDC codes at the point of administration, reducing the risk of submitting a stale or inactive NDC on a claim.

Billing units for HCPCS Code J9202

In practice, one billable unit of J9202 equals exactly 3.6 mg. For the standard monthly implant, bill 1 unit per administration. Never bill fractional units or attempt to report the 10.8 mg three-month depot as 3 units of J9202. That formulation has its own HCPCS code, and billing it as three J9202 units therefore constitutes a coding error.

• Monthly 3.6 mg implant: 1 unit of J9202 per administration
• 3-month 10.8 mg depot: Use the separate HCPCS code for that formulation, not J9202
• Administration code: J9202 covers the drug only. Bill the appropriate injection/administration CPT code separately (e.g., 96401 for subcutaneous chemotherapy)
• Maximum units: UHC’s packaged drugs list confirms a maximum of 1 unit per NDC per claim for J9202

As a result, integrating your drug administration records with prescription management software that captures dose, lot number, and administration date reduces transcription errors when building the claim.

Medicare reimbursement rates for HCPCS Code J9202

Medicare Part B reimburses J9202 under the buy-and-bill model. Reimbursement is based on the drug’s Average Sales Price (ASP) plus a 6% add-on, which is the standard Medicare Part B drug payment methodology. CMS updates ASP-based rates quarterly, so the exact payment amount changes four times per year.

To find the current quarter’s ASP payment limit for J9202, use the CMS Physician Fee Schedule lookup tool or CMS’s quarterly ASP drug pricing files. The payment amount varies by geographic location due to the geographic practice cost index (GPCI) adjustments applied to the practice expense component.

ASP methodology explained

Specifically, ASP is a weighted average of a manufacturer’s net selling prices to all US purchasers, minus certain discounts and rebates. CMS sets the Medicare payment rate at ASP + 6%. Consequently, practices that acquire Zoladex at acquisition cost below ASP may retain the margin between acquisition cost and the Medicare payment rate. This margin is the economic foundation of the buy-and-bill model for oncology drugs.

In contrast, WAC (Wholesale Acquisition Cost) and AWP (Average Wholesale Price) are higher benchmarks often cited by commercial payers. When contracting with commercial insurers, therefore, verify whether the contract reimburses at ASP, WAC, AWP, or a percentage of AWP. These distinctions directly affect your practice’s reimbursement margin on goserelin.

Place of service impact

Medicare pays different rates depending on where the drug is administered. For example, office settings (place of service 11) typically receive a higher facility-versus-non-facility distinction adjustment than hospital outpatient departments (place of service 22) for certain services. As a result, confirm the applicable rate for your place of service code on the CMS fee schedule lookup.

Manage oncology drug billing in one place

Pabau helps oncology and urology practices track drug administration, wastage, NDC codes, and payer authorizations. Reduce claim denials and keep your revenue cycle running.

Book a demo

Modifiers used with HCPCS Code J9202

Several modifiers may apply to J9202 claims depending on the clinical scenario. Getting modifier selection wrong is one of the most common denial causes for Part B drug claims.

JW modifier: discarded drug

The JW modifier reports the amount of a drug discarded from a single-dose vial or package. Specifically, CMS requires providers to report discarded amounts using JW on a separate line. For J9202, which is a single-dose implant, wastage is rare but can occur if the implant is damaged or withdrawn but not administered. In that case, the JW line uses the same HCPCS code (J9202) with the amount discarded in units.

JZ modifier: zero waste

Effective January 1, 2023, CMS requires providers to append the JZ modifier when there is no discarded drug from a single-dose vial. Therefore, for a J9202 claim where the full 3.6 mg implant is administered with zero waste, the claim line requires JZ. Failing to append either JW or JZ when CMS requires it will result in a claim edit under the agency’s JW/JZ enforcement policy. Furthermore, CMS explicitly lists J9202 in the JW/JZ Modifier Policy HCPCS Codes document.

Other applicable modifiers

• GY: Item or service statutorily excluded from Medicare coverage. Use when administering goserelin for a non-covered indication and the patient has agreed to pay out of pocket.
• GA: Waiver of liability on file. Use when the service may not be covered and you have an Advance Beneficiary Notice (ABN) on file.
• 59: Distinct procedural service. May apply when J9202 is administered alongside other drug injections on the same date of service, per NCCI edits.
• LT / RT: Not typically applicable for subcutaneous implants but check payer-specific requirements.

As a result, maintaining consistent modifier documentation is a key part of medical practice compliance. Instead of applying modifiers after the fact, build modifier selection into your billing workflow from the start.

Coverage policies and prior authorization for HCPCS Code J9202

Coverage for J9202 varies by payer and plan year. Medicare follows the guidance in CMS Article A52453, which establishes limited coverage for LHRH analogs including J9202 tied to the covered ICD-10 codes listed above. Commercial payers may use their own medical policies that differ from CMS guidance.

Medicare coverage framework

Under Medicare Part B, J9202 is covered when administered for a diagnosis listed in CMS Article A52453. Medicare coverage is “limited coverage,” meaning the claim must carry one of the approved primary ICD-10 codes. Payers will deny claims submitted without a covered diagnosis code as not medically necessary. CMS maintains the article in the Medicare Coverage Database — check it at the start of each plan year for updates.

Commercial payer requirements

Many commercial payers require prior authorization for J9202, particularly for breast cancer and endometriosis indications. Prostate cancer typically has a more straightforward approval pathway, but authorizations still expire and must be renewed with each treatment cycle in many plans. Contact payer provider relations or check the payer’s online authorization lookup to confirm requirements before scheduling administration.

UHC’s published NDC packaged-drugs policy confirms maximum units per claim for J9202. Evicore’s Medical Oncology Master Drug List (effective Q2 2025) classifies J9202 under Medical Oncology as a Primary LHRH drug, meaning Evicore-managed plans may require managed oncology authorization review.

Related HCPCS codes for LHRH analogs

When a patient’s therapy changes or a payer substitutes a different LHRH analog, you will need the correct HCPCS code for that drug. The LHRH analog code family includes:

• J1950: Leuprolide acetate (Lupron Depot), per 3.75 mg
• J9217: Leuprolide acetate (for depot suspension), 7.5 mg
• J9219: Leuprolide acetate implant, 65 mg
• J9225: Histrelin acetate implant, 50 mg (Vantas)
• J9226: Histrelin acetate implant, 50 mg (Supprelin)
• J3315: Triptorelin pamoate, per 3.75 mg

Never substitute one LHRH analog HCPCS code for another. Each code maps to a specific drug and dose. Submitting J9202 when a different LHRH analog was administered is a coding error subject to audit correction. Robust digital intake and administration forms that capture the exact drug name, NDC, and dose at the point of care help prevent substitution errors from reaching the billing team.

Revenue cycle tips for J9202 billing

Oncology and urology practices with high J9202 volume benefit from a structured billing workflow. In particular, the following steps reduce denial rates:

• Verify prior authorization status before each administration, not just at treatment initiation
• Confirm the active NDC matches the billed HCPCS code at the time of claim submission
• Append JZ or JW on every J9202 claim line
• Submit the administration CPT code on a separate claim line with the correct place of service
• Keep documentation of the covered ICD-10 diagnosis in the patient’s record and attach it to the claim where payer portals permit
• Track authorization expiration dates for each treatment cycle, especially for breast cancer and endometriosis patients

Using practice management software that connects clinical documentation, drug administration records, and billing in one system significantly reduces the gap between administration and claim submission. Moreover, delays in submission increase the risk that authorization numbers expire or payer policies change before the claim is processed.

Conclusion

HCPCS Code J9202 billing requires precision at every step: the correct dose, the correct NDC, the correct ICD-10 primary diagnosis, and the mandatory JW or JZ modifier. In other words, one missing element is enough to trigger a denial on a drug that may cost hundreds of dollars per administration.

Pabau’s claims management software gives oncology and urology practices a connected workflow from drug administration through claim submission, reducing the coding gaps that drive J9202 denials. To see how Pabau supports billing accuracy across your practice, book a demo.

Continue your research

Need a compliant framework for drug administration documentation? Pabau’s digital forms let you capture drug name, NDC, dose, and administration details at the point of care, keeping records audit-ready.

Managing multi-drug oncology or urology billing? Pabau’s inventory management software tracks lot numbers, NDC codes, and stock levels so your billing team always has accurate dispensing data.

Want to reduce claim denials across your whole practice? How practice management software works covers how connecting clinical and billing workflows closes the gaps that drive preventable rejections.

Frequently Asked Questions